Cookies auf der KCI-Website
Wir verwenden Cookies, um Ihnen die Nutzung unserer Website zu erleichtern. Weitere Informationen zu Cookies und deren Verwendung erhalten Sie hier Privacy Policy. Um Ihnen das Navigieren zu erleichtern, empfehlen wir Ihnen, die Cookies zu akzeptieren.
Eingabehilfen | Sitemap | Kontaktieren Sie uns | KUNDENDIENST ANRUF 0848 848 900
Startseite  |  Einsatzgebiete  |  Produkte  |  Klinische Evidenz  |  Fortbildung & Training  |  Für Patienten  |  Kundendienst
Sie sind hier Startseite > Nachrichten & Medien > Acelity Announces Expansion of Prevena™ Therapy Portfolio with Addition of Shorter Peel & Place™ System

Acelity Announces Expansion of Prevena™ Therapy Portfolio with Addition of Shorter Peel & Place™ System

Freigegeben : 8 Oktober 2015
KCI, Leader in Advanced Wound Care Solutions

New system allows clinicians to better manage smaller incisions and anatomically challenging areas


SAN ANTONIO, October 8, 2015 – Acelity announced today that it is extending its Prevena™ Therapy portfolio with the addition of a new, shorter Peel & Place™ System. The dressing in the Peel & Place™ - 13 System is identical to the existing system except for its shorter length and is designed for the management of linear incisions up to 13 centimeters in length. The Prevena™ Peel & Place™ - 13 System is now available in the United States and Europe, and expanded availability globally is anticipated in January 2016.


This expansion of the Prevena™ Peel & Place™ product line enables a surgeon to target negative pressure therapy for incisions in anatomically challenging areas of the body. The new 13cm dressing is provided either separately or in combination with the portable Prevena™ 125 Therapy Unit that provides negative pressure therapy in a small, easy to operate device that can transition home with the patient. This system will make Prevena™ Therapy available to a wider range of incisions.


“The smaller profile of the Prevena™ Peel & Place™ -13 System will be instrumental in helping deliver negative pressure therapy for patients whose incisions are located in challenging areas of the body,” said Mahmoud B Malas, M.D., Director of Endovascular Surgery, Johns Hopkins Bayview Medical Center. “Surgeons now have a new option designed specifically for smaller incisions to help them better manage patient outcomes.”


“Reducing surgical site complications is critically important to hospitals and health systems around the world,” said Ron Silverman, M.D., Chief Medical Officer, Acelity. “This expansion provides surgeons and additional patient populations with the power and clinical benefits of Prevena™ Therapy in the management of closed surgical incisions, as demonstrated by a growing body of evidence.”

The Prevena™ Incision Management System is the first powered negative pressure product designed specifically for management of closed surgical incisions that continue to drain following sutured or stapled closure. The Prevena™ System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material. The Prevena System has been evaluated clinically in a number of surgeries at risk of complications, such as sternotomy, cesareans, hysterectomies, orthopedic and vascular groin incisions, all with positive clinical outcomes.*

*Bibliography available upon request.

About Acelity

Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,700 people around the world.


For more information, contact:

Kathryn Skeen
Corporate Communications
Phone: +1-210-882-2067

    Caleb Moore
Investor Relations
Phone: +1-210-255-6433


  • Share on
  • Share on Twitter
  • Besuchen Sie unsere YourTube Seite

Wichtige Mitteilung für Patienten

Rechtliches | Datenschutzrichtlinien | Kontaktieren Sie uns

© 1998 – 2013 KCI Licensing, Inc. Alle Rechte vorbehalten.    DSL# 09-03-193.CH-GER

Die Informationen auf dieser Website wurden ausschliesslich zur Nutzung in Schweiz / KCI Medical GmbH bereitgestellt. Diese Website enthält Informationen über Produkte, die möglicherweise nicht in allen Ländern verfügbar sind. Es ist ausserdem möglich, dass sie von den zuständigen Behörden in bestimmten Ländern noch nicht oder nicht für bestimmte Indikationen zugelassen sind.